In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc.

NEW YORK, NY / ACCESSWIRE / October 6, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new CEO interview with First Wave BioPharma.

Toni had the pleasure of recently conducting the Interview with James Sapirstein, Chief Executive Officer of First Wave BioPharma, Inc. (NASDAQ:FWBI). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.

Access this interview in its entirety at https://tradersnewssource.com/fwbi-interview/

Traders News Source, Thursday, October 6, 2022, Press release picture
Traders News Source, Thursday, October 6, 2022, Press release picture

James Sapirstein CEO, First Wave BioPharma

James Sapirstein has served for over thirty-seven years in the pharmaceutical industry. He is currently the Chairman, CEO and President of First Wave BioPharma (NASDAQ: FWBI).

He began his career in 1984 with Eli Lilly, moving to Hoffmann-LaRoche in 1987, where he served for almost a decade on various commercial teams in the US and Internationally. He joined Bristol Myers Squibb as the Director of International Marketing in the Infectious Diseases group in 1996. While at BMS, he worked on several important HIV/AIDS projects including Secure the Future.

Mr. Sapirstein started his career in smaller biotech companies when he later joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President, Metabolic and Endocrinology, for Serono Laboratories. Later, in 2006, he became the founding CEO of Tobira Therapeutics, then a private

company. Tobira Therapeutics was acquired by Allergan in 2016. In 2012, Mr. Sapirstein became the CEO of Alliqua, Inc. Thereafter, he served as CEO of Contravir Pharmaceuticals from March 2014 until October 2018. All of these are publicly listed companies. Mr. Sapirstein has raised over $300 Million dollars in venture capital and public capital markets financing in his various engagements as CEO. He was named as a Finalist for the Ernst & Young Entrepreneur of the Year award in 2015 as well as in 2016.

Mr. Sapirstein holds board positions on Enochian Biosciences. He was Chairman of the Board for BioNJ, an association of biopharma industries in New Jersey from Feb 2017-Feb 2019. In addition, he is a Board Director for BIO (Biotechnology Innovation Organization), the leading biotechnology trade organization promoting public policy and networking in the healthcare space, where he sits on the Emerging Companies Section Governing Board.

Mr. Sapirstein received a BS (Pharmacy) from Rutgers University in 1984 and an MBA from Fairleigh Dickinson University in 1997.

Interview Highlights:

Traders News Source Toni Loudenbeck and CEO James Sapirstein covers the future vision for the company, what near term catalyst at FWBI could be the biggest benefit to shareholders, update on the IND application for adrulipase, plus much more in this interview.

Access this interview in its entirety at https://tradersnewssource.com/fwbi-interview/

About First Wave BioPharma, Inc.

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies - the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn's disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

First Media Contact:

Tiberend Strategic Advisors, Inc.
Bill Borden
(732) 910-1620
bborden@tiberend.com
Dave Schemelia
(609) 468-9325
dschemelia@tiberend.com

About Traders News Source (TNS)

Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit: https://tradersnewssource.com/fwbi-interview/

Media Contact

Mark Roberts, Editor@TradersNewsSource.com

SOURCE: Traders News Source LLC



View source version on accesswire.com:
https://www.accesswire.com/719298/In-a-New-Audio-Interview-Toni-Loudenbeck-of-Traders-News-Source-Interviews-James-Sapirstein-CEO-First-Wave-BioPharma-Inc